Modified recombinant human endostatin and uses thereof
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Aug 12, 2014
Grant Date -
Aug 19, 2010
app pub date -
Sep 4, 2008
filing date -
Sep 5, 2007
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Provided is a kind of modified recombinant human endostatin that has the structure of CH3O—(CH2CH2O)m—CH2CH2CH2—NαH-Endostar, wherein the average molecular weight of CH3O—(CH2CH2O)m—CH2CH2CH2— is 20-40 kD. The modified recombinant human endostatin enhances the stability in vivo, improves blood drug concentration, prolongs half-life, markedly increases the activity of inhibiting the endothelial cells proliferation, thus reduces drug dosage and decreases administration frequency. Its application for preparing anti-tumor pharmaceutical compositions is also provided.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully